Novo Nordisk, a Denmark-based diabetes care equipment manufacturer, has launched its latest insulin delivery device NovoPen Echo in the US.
Designed to give children and parents increased confidence, NovoPen Echo combines dosing in half-unit increments with an easy-to-use memory function.
Half-unit dose increments allow for finer adjustments that can be particularly important for children. Additionally, 12 fun removable skins are available for a customized look, including kid-friendly designs.
The memory function records the dose and time passed since the last injection.
Novo Nordisk claims that NovoPen Echo is the first and only pen device available in the US with half-unit dosing and a memory function.
Novo Nordisk NovoLog brand team vice president George McAvoy said: "We are excited to make NovoPen Echo available in the United States for patients and believe this pen can help patients fine tune their dosing while offering added reassurance they are managing their diabetes appropriately."
NovoPen Echo has already been launched in Europe, Canada, and Israel. The device is available to the patients for use with NovoLog PenFill cartridges. NovoLog is a man-made insulin used to control high blood sugar in adults and children with diabetes mellitus.
Image: Novo Nordisk launches NovoPen Echo in US. Photo: Courtesy of Novo Nordisk A/S.